Renal sympathetic denervation: Effect on ambulatory blood pressure and blood pressure variability in patients with treatment-resistant hypertension. The ReShape CV-risk study

Journal of Human Hypertension

Volumn 30, Issue 3, 2016, Pages 153-157

  Miroslawska, A ^a   Solbu, M ^a   Skjolsvik E ^a   Toft, I ^a   Steigen, T K ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; KIDNEY DENERVATION; MALE; MAXIMUM TOLERATED DOSE; OPEN STUDY; RENAL SYMPATHETIC DENERVATION; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESISTANT HYPERTENSION; BLOOD PRESSURE; CLINICAL TRIAL; HYPERTENSION; INNERVATION; KIDNEY; MIDDLE AGED; SALVAGE THERAPY; SYMPATHECTOMY;

BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; SALVAGE THERAPY; SYMPATHECTOMY;

EID: 84958115027     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.69     Document Type: Article

References (30)

1. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Jama 2003; 289(18): 2363-2369.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121(7): 948-954.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217-223.
4. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57(5): 898-902.
5. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014; 63(5): 991-999.
6. Parati G, Ochoa JE, Salvi P, Lombardi C, Bilo G. Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care 2013; 36(Suppl 2): S312-S324.
7. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K et al. Catheterbased renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373(9671): 1275-1281.
8. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376(9756): 1903-1909.
9. Mendelsohn FO. Does complete renal denervation translate into superior clinical outcomes? Lessons learned from denervation of accessory renal arteries. Clin Res Cardiol 2014; 103(9): 681-683.
10. Patel HC, Dhillon PS, Mahfoud F, Lindsay AC, Hayward C, Ernst S et al. The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol 2014; 103(5): 337-344.
11. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Eng J Med 2014; 370(15): 1393-1401.
12. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357.
13. Bilo G, Giglio A, Styczkiewicz K, Caldara G, Maronati A, Kawecka-Jaszcz K et al. A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J hypertens 2007; 25(10): 2058-2066.
14. Pierdomenico SD, Di Nicola M, Esposito AL, Di Mascio R, Ballone E, Lapenna D et al. Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 2009; 22(8): 842-847.
15. Bombelli M, Fodri D, Toso E, Macchiarulo M, Cairo M, Facchetti R et al. Relationship among morning blood pressure surge, 24-hour blood pressure variability, and cardiovascular outcomes in a white population. Hypertension 2014; 64(5): 943-950.
16. Palatini P, Reboldi G, Beilin LJ, Casiglia E, Eguchi K, Imai Y et al. Added predictive value of night-time blood pressure variability for cardiovascular events and mortality: the Ambulatory Blood Pressure-International Study. Hypertension 2014; 64(3): 487-493.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604-612.
18. Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P et al. Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension: Six-Month Results From the Prague-15 Study. Hypertension 2014; 65(2): 407-413.
19. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62(3): 526-532.
20. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348(24): 2407-2415.
21. Redon J, Lurbe E. Ambulatory blood pressure monitoring is ready to replace clinic blood pressure in the diagnosis of hypertension: con side of the argument. Hypertension 2014; 64(6): 1169-1174, discussion 1174.
22. Persu A, Azizi M, Jin Y, Volz S, Rosa J, Fadl Elmula FE et al. Hyperresponders vs. nonresponder patients after renal denervation: do they differ? J Hypertens 2014; 32(12): 2422-2427.
23. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46(1): 156-161.
24. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension 2011; 57(1): 3-10.
25. Mancia G, Di Rienzo M, Parati G, Grassi G. Sympathetic activity, blood pressure variability and end organ damage in hypertension. J Hum Hypertens 1997; 11 (Suppl 1): S3-S8.
26. Boggia J, Asayama K, Li Y, Hansen TW, Mena L, Schutte R. Cardiovascular risk stratification and blood pressure variability on ambulatory and home blood pressure measurement. Curr Hypertens Rep 2014; 16(9): 470.
27. Zuern CS, Rizas KD, Eick C, Stoleriu C, Bunk L, Barthel P et al. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol 2012; 3: 134.
28. Tsioufis C, Papademetriou V, Tsiachris D, Kasiakogias A, Kordalis A, Thomopoulos C et al. Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study. Int J Cardiol 2015; 180: 237-242.
29. Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Bjorklund-Bodegard K et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension 2010; 55(4): 1049-1057.
30. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375(9718): 906-915.